CarboGen was founded in 1990 at the University of Zurich. Demand for the early-phase supply and process research services saw the company expand to premises at Aarau and subsequently Hunzenschwil (Neuland).
AMCIS was founded in 1982. It formed a joint venture with an American pharmaceutical company in 1994 to undertake exclusive process development and cGMP manufacturing. The joint venture was concluded in 2000.
Both CarboGen and AMCIS were acquired by Solutia in 2000. The Switzerland base of both companies and the complementary services meant that the combination of the two organizations could effectively service chemistry scale-up from bench to commercial supply.
Following six years under the Solutia umbrella the integration process was concluded with the merger of CarboGen and AMCIS into the single legal entity called CARBOGEN AMCIS AG.
CARBOGEN AMCIS AG was acquired by Dishman Pharmaceuticals and Chemicals Ltd. in August 2006.
In 2007, CARBOGEN AMCIS Ltd. was created in Manchester when it integrated SynProTec DRC, also owned by Dishman Pharmaceuticals and Chemicals Ltd.
The new organization can now offer the rapid supply of early-phase cGMP material, as well as the later phase non-GMP and GMP supply of small API quantities. With the possible expansion into the nonGMP services of Dishman the organization allows the customers a breadth of flexible, efficient and cost effective development services from a single partner.
In 2012 CARBOGEN AMCIS acquired Creapharm Parenterals (former MP5) a contract manufacturer of clinical trial materials focused on formulation, aseptic filling, and lyophilization of APIs, cytotoxics and other highly-potent drugs as well as biologics. The wholly-owned French subsidiary, which operates under the newly formed entity CARBOGEN AMCIS SAS, provides comprehensive formulation, lyophilization services and sterile GMP capabilities for the supply of drug-products for preclinical studies and clinical trials (Phase I, II & III).